Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20087177rdf:typepubmed:Citationlld:pubmed
pubmed-article:20087177lifeskim:mentionsumls-concept:C0023467lld:lifeskim
pubmed-article:20087177lifeskim:mentionsumls-concept:C0599894lld:lifeskim
pubmed-article:20087177lifeskim:mentionsumls-concept:C0600558lld:lifeskim
pubmed-article:20087177lifeskim:mentionsumls-concept:C0449445lld:lifeskim
pubmed-article:20087177pubmed:issue2lld:pubmed
pubmed-article:20087177pubmed:dateCreated2010-2-10lld:pubmed
pubmed-article:20087177pubmed:abstractTextAcute myeloid leukemia (AML) is a heterogeneous group of clonal disorders which is treated with similar regimens despite the heterogeneity. The treatment approach for many years has used combination chemotherapy, with usually an anthracycline and cytarabine as the foundation. In the present review we will present new data from recently completed trials that have demonstrated advances in the treatment of AML.lld:pubmed
pubmed-article:20087177pubmed:languageenglld:pubmed
pubmed-article:20087177pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20087177pubmed:citationSubsetIMlld:pubmed
pubmed-article:20087177pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20087177pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20087177pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20087177pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20087177pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20087177pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20087177pubmed:statusMEDLINElld:pubmed
pubmed-article:20087177pubmed:monthMarlld:pubmed
pubmed-article:20087177pubmed:issn1531-7048lld:pubmed
pubmed-article:20087177pubmed:authorpubmed-author:RoweJacob MJMlld:pubmed
pubmed-article:20087177pubmed:authorpubmed-author:FernandezHugo...lld:pubmed
pubmed-article:20087177pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20087177pubmed:volume17lld:pubmed
pubmed-article:20087177pubmed:ownerNLMlld:pubmed
pubmed-article:20087177pubmed:authorsCompleteYlld:pubmed
pubmed-article:20087177pubmed:pagination79-84lld:pubmed
pubmed-article:20087177pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:20087177pubmed:meshHeadingpubmed-meshheading:20087177...lld:pubmed
pubmed-article:20087177pubmed:meshHeadingpubmed-meshheading:20087177...lld:pubmed
pubmed-article:20087177pubmed:meshHeadingpubmed-meshheading:20087177...lld:pubmed
pubmed-article:20087177pubmed:meshHeadingpubmed-meshheading:20087177...lld:pubmed
pubmed-article:20087177pubmed:meshHeadingpubmed-meshheading:20087177...lld:pubmed
pubmed-article:20087177pubmed:meshHeadingpubmed-meshheading:20087177...lld:pubmed
pubmed-article:20087177pubmed:meshHeadingpubmed-meshheading:20087177...lld:pubmed
pubmed-article:20087177pubmed:meshHeadingpubmed-meshheading:20087177...lld:pubmed
pubmed-article:20087177pubmed:meshHeadingpubmed-meshheading:20087177...lld:pubmed
pubmed-article:20087177pubmed:meshHeadingpubmed-meshheading:20087177...lld:pubmed
pubmed-article:20087177pubmed:meshHeadingpubmed-meshheading:20087177...lld:pubmed
pubmed-article:20087177pubmed:year2010lld:pubmed
pubmed-article:20087177pubmed:articleTitleInduction therapy in acute myeloid leukemia: intensifying and targeting the approach.lld:pubmed
pubmed-article:20087177pubmed:affiliationDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. hugo.fernandez@moffitt.orglld:pubmed
pubmed-article:20087177pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20087177pubmed:publicationTypeReviewlld:pubmed